Boehringer Ingelheim announces new R&D strategy and five-year investment plan. Over the next 5 years, the company is committed to investing a total of 11 billion euros in its new R&D program, of which 5 billion in preclinical and 1.5 billion in collaborations with external partners. The company aims to develop next-generation therapies and maintain its competitive position.
The new R&D strategy embraces so-called 'open innovation' with external collaborations that best combine the capabilities and experience of Boehringer Ingelheim and research in new emerging fields for the discovery of new drugs.
“The 11 new launches in 2014 and 2015 testify to the extraordinary capacity of Boehringer Ingelheim's internal Research & Development – comments Andreas Barner, Chairman of the Board of Boehringer Ingelheim – the new strategy and the new program reflect our long-term, focused to sustainable growth and will enable us to continue our long and successful tradition of delivering therapeutic innovations of great value to patients.”
(BDC – November 12, 2015 PharmaKronos)
Related news: In Boehringer strike on October 30 against 176 layoffs. The press release of the RSU
